BPC-157 oral vs injection: differences, evidence and safety

Verdict: Oral BPC-157 has animal evidence and two registered human studies, neither of which has posted results; injected BPC-157 has animal evidence, the only measured bioavailability (in rats and dogs) and three tiny human pilot studies. Neither route is FDA approved, and no study has measured how much oral BPC-157 reaches the blood.

BPC-157 is an experimental 15-amino-acid peptide that is unusually stable in stomach acid, which is why it is sold both as capsules and as injections. The open question behind “BPC-157 oral vs injection” is whether swallowed BPC-157 is absorbed, and the honest answer is that nobody has measured it in any species. The FDA reviewers who examined BPC-157 in 2026 found no human pharmacokinetic data after oral or subcutaneous use, and USADA lists it as prohibited in sport with no exception for capsules.

Item	Oral BPC-157	Injected BPC-157
US FDA status	Not approved for any use	Not approved for any use
Compounding (503A/503B)	Withdrawn from Category 2 by nominators; FDA staff advised against the 503A list, but the PCAC voted 8–6 (1 abstention) on 2026-07-23 to recommend it, per trade press (AJMC); advisory, no FDA rule yet	Same; FDA flags immunogenicity risk for injectable forms
WADA 2026	Prohibited, S0 (non-approved substances)	Prohibited, S0 (non-approved substances)
Strongest evidence	Animal (rats, drinking water)	Animal; human case series (n=12 to 16)
Human trials	1 phase 1 and 1 single-arm supplement study, neither with results (NCT02637284, NCT07752381)	1 registered, not yet recruiting: NCT07803250
Measured bioavailability	None in any species	14–19% (rats), 45–51% (dogs), intramuscular
Last checked	2026-10-18	2026-10-02

Oral vs injected BPC-157 at a glance

Feature	Oral BPC-157	Injected BPC-157
What it is	Capsules, tablets or liquid swallowed	Solution injected under the skin, into muscle, a joint or a vein
Same molecule?	Yes, 15 amino acids	Yes, 15 amino acids
Main research focus	Gut lesions, fistulas, bowel healing in rats	Tendon, muscle, ligament healing in rats
Stomach stability	Reported resistant to gastric juice in vitro	Not relevant (bypasses the gut)
Measured bioavailability	Never measured	14–51%, species-dependent (He 2022)
Half-life in blood	Unknown	Under 30 minutes (rats, dogs)
Human evidence	None published	3 uncontrolled pilots, 30 people in total (review)
Registered trials	1 phase 1 (no results); 1 open-label supplement study	1 phase 1 not yet recruiting
Approval status	Not approved	Not approved
WADA	Prohibited (S0)	Prohibited (S0)
Timelines in studies	Rat outcomes measured from day 3 to day 90	Rat outcomes day 1 to day 90; knee survey at 6–12 months
Main safety concerns	Impurities; unknown absorption	Immunogenicity, aggregation, sterility, site reactions

What is oral BPC-157?

Oral BPC-157 is the same synthetic peptide taken by mouth. It copies part of a protein originally isolated from human gastric juice, and FDA’s briefing notes that it was reported resistant to breakdown in gastric juice in vitro [Lab]. That stability is the main argument for swallowing it. The same FDA document says BPC-157 is marketed in the US in dietary supplement capsules and tablets, although it is not a component of any approved drug. In rat studies, “oral” usually meant BPC-157 dissolved in drinking water or given by stomach tube, which is not the same thing as a capsule made for people.

What is injected BPC-157?

Injected BPC-157 is the peptide given under the skin, into muscle, into a joint, into the bladder wall or into a vein. Many rat healing studies used injections into the abdominal cavity (intraperitoneal), such as the Achilles tendon-to-bone study by Krivic and colleagues [Animal]. Injection is also the only route with a published bioavailability figure. Apart from two rectal-enema studies reported only as meeting abstracts, every human study has used injection or infusion. The one registered injection trial, after rotator cuff surgery, uses subcutaneous injection.

How the routes work differently

• Getting into the body. Oral: the peptide must survive the stomach, then the intestine, cross the gut wall and pass the liver; a 2026 review found no published data on intestinal stability, gut-wall permeability or liver extraction for BPC-157. Injected: intramuscular BPC-157 reached about 14–19% bioavailability in rats and 45–51% in dogs in the only formal pharmacokinetic study [Animal].
• Where it may act. Oral: the same review notes that gut effects seen after oral dosing in rodents could come from direct contact with the gut lining rather than absorption, and the studies do not separate the two. Injected: part of the dose is absorbed from the injection site into the blood, where it is broken down into small fragments and amino acids, with a half-life under 30 minutes.
• Immune reactions. Oral: FDA’s reviewers wrote that the inherent immunogenic risk of oral BPC-157 “is likely to be low,” while still raising concerns about impurities. Injected: the same reviewers said subcutaneous and nasal routes are generally linked to more immunogenicity than oral or rectal routes, and FDA’s compounding safety page warns of immunogenicity risk “for certain routes of administration.”

What bioavailability studies show, and what they don’t

Bioavailability is the share of a dose that reaches the bloodstream intact. For BPC-157 it has been measured once, in a 2022 study in rats and beagle dogs that gave the peptide intravenously and intramuscularly: mean absolute bioavailability after intramuscular injection was about 14–19% in rats and 45–51% in dogs, and the half-life of the intact peptide was under 30 minutes [Animal]. The study had no oral arm. FDA’s briefing gives the intravenous half-life as 5.3 minutes in dogs and 15.2 minutes in rats, and it concludes the short half-life likely reflects breakdown by enzymes in blood and tissue.

For the oral route, the evidence is a list of gaps. A 2026 review in Pharmaceutics lists oral bioavailability “in any species” and subcutaneous pharmacokinetics among the data that do not exist, and it judges plain oral preparations unlikely to reach meaningful blood levels without an absorption enhancer. The FDA reviewers found no animal pharmacokinetic or toxicity studies of BPC-157 by the oral, subcutaneous, nasal or rectal routes. In two human studies of BPC-157 given as an enema, the authors reported that it was not detected in plasma.

A useful benchmark is oral semaglutide, an approved peptide pill. Its FDA label puts absolute bioavailability at about 0.4% to 1%, even though it is co-formulated with SNAC, an absorption enhancer [Approved label]. Some pages state that oral BPC-157 has 10–30% bioavailability; we found no study that measured it.

Evidence head-to-head

Outcome	Oral: best evidence	Injection: best evidence
Absorption into blood	None measured	Animal: He 2022 (rats, dogs)
Gut fistula healing	Animal: Klicek 2008	Animal: Klicek 2008 (same study)
Short bowel syndrome	Animal: Sever 2009	Animal: Sever 2009 (same study)
Ligament healing	Animal: Cerovecki 2010	Animal: Cerovecki 2010 (same study)
Muscle-tendon junction	Animal: Japjec 2021	Animal: Japjec 2021 (same study)
Knee pain	No study	Human case series, n=16: Lee 2021
Bladder pain (interstitial cystitis)	No study	Human case series, n=12: Lee 2024
Human safety	Phase 1 never reported: NCT02637284	Human pilot, n=2: Lee 2025 (intravenous)

The pattern is clear. In the rat studies that tested both routes, the oral and injected groups improved together: Klicek and colleagues reported that BPC-157 “accelerated parenterally or perorally” the healing of colon fistulas, using the same dose levels by both routes [Animal]. The ligament study by Cerovecki found intraperitoneal, drinking-water and cream applications all effective [Animal]. None of these studies measured blood levels, so they show that both routes changed outcomes in rats, not how much peptide was absorbed. A 2025 review called for studies that compare oral and intraperitoneal dosing in one model to make results more reliable.

On the human side, every full published study used injection or infusion; the only other human data are two rectal-enema meeting abstracts. A 2025 systematic review of 36 musculoskeletal studies found 35 preclinical studies and one clinical study, and no clinical safety data.

Oral vs injection BPC-157: which has more evidence for which goal?

For gut-related outcomes the evidence is in rats only, and the main studies tested oral and injected BPC-157 side by side, so neither route has clearly more support. Rats given BPC-157 in drinking water or by injection after bowel resection gained weight above their pre-surgery values, while untreated rats lost weight [Animal]. FDA’s briefing also summarises rat studies in which oral and injected BPC-157 both prevented drug-induced stomach and liver lesions [Animal].

Injected BPC-157 has more evidence for joint, tendon and muscle outcomes, but only as rat studies and small uncontrolled human reports. In a retrospective survey of people given knee injections, 14 of 16 reported relief, including 3 of the 4 who also received thymosin beta-4, with no measurement tools used [Human (case series, n=16)]. Injected BPC-157 is also the route planned in a placebo-controlled phase 1 trial after rotator cuff surgery with 30 planned participants, not yet recruiting.

These are statements about where evidence exists, not a reason to use either form. A clinician is the person to decide whether any treatment fits a specific condition. Our comparison method explains how we grade these studies.

Can the routes be combined?

Some rat studies ran oral and injected groups side by side, but none gave both routes to the same animals as a combined treatment. No controlled human study has tested oral and injected BPC-157 together, or compared the two routes head to head. BPC-157 is also often sold in blends with other peptides; our pages on BPC-157 vs TB-500 and the Wolverine stack vs KLOW cover what is known about those combinations.

Safety and regulatory status

United States. BPC-157 is not approved by FDA in any form. USADA notes that some websites advertise it “can be injected or taken orally” for many purposes and calls these unproven claims. FDA lists BPC-157 among substances withdrawn from Category 2 by their nominators, which is not an approval and not a move to Category 1. FDA staff then reviewed it for ulcerative colitis at the July 23, 2026 compounding advisory committee, and their briefing concluded that the criteria weigh against adding it to the 503A bulks list, although the committee voted 8–6, with 1 abstention, to recommend listing, according to trade-press reports (AJMC), because FDA has posted no minutes. Advisory committees make non-binding recommendations, and FDA says it makes no final decision until the advisory process and its reviews are complete.

Oral-specific risks. FDA’s reviewers rated oral immunogenic risk as likely low but noted the possibility of peptide-related impurities. Because absorption is unknown, a person taking capsules cannot know how much peptide reaches the blood. A supplement-company study of BPC-157 gummies, NCT07752381, was single-arm and unblinded, enrolled 40 people, and has posted no results.

Injection-specific risks. FDA’s briefing states concern about immunogenicity of injectable BPC-157 because of possible aggregation (peptide molecules clumping) and impurities. Reports to FDA’s adverse event database include injection site reaction, shortness of breath, and darkening of the skin and gums, although FDA notes it is unclear whether BPC-157 caused them. Injected products must also be sterile, and a 2026 review found that no pharmaceutical-grade BPC-157 formulation has been developed or validated.

Sport. USADA lists BPC-157 as prohibited under the WADA list’s S0 category for non-approved substances, with no exception for oral products. Anti-doping scientists have validated a urine test that detects BPC-157 down to 0.1 ng/mL along with a stable metabolite. A 2025 review stated that WADA no longer lists BPC-157, but that is out of date: USADA’s current guidance says it is prohibited under S0.

For a wider look at how BPC-157 is discussed in popular media, see our page on the peptides discussed on the Joe Rogan podcast.

How long do effects take in studies?

Only animal studies report timelines by route. In the colon fistula study summarised by FDA, fistulas in rats given BPC-157 orally or by injection were about 40% smaller than in untreated rats from day 3, and appeared closed by day 28 [Animal]. In the bowel-resection study, weight gain began immediately with both routes and gut-wall changes were measured at 7, 14, 21 and 28 days [Animal]. The muscle-tendon junction study saw well-oriented repaired tissue at 28 and 42 days with both routes [Animal]. In humans, the knee survey asked people about pain 6 months to 1 year after injection, which says little about onset [Human (case series, n=16)].